CoChat
Sign Up
Cited by 143Pancreatic function and diabetesDiabetes and associated disordersTissue Engineering and Regenerative Medicine

Advancing islet transplantation: from engraftment to the immune response

Open access
Gibly, R. F., Graham, J. G., Luo, X., Lowe, W. L., Hering, B. J., Shea, L. D.·2011·Diabetologia
DOI 10.1007/s00125-011-2243-0PMC PMC3193607
Open this paper in CoChat — free accountOpen PDF

Abstract

The promise and progress of islet transplantation for treating type 1 diabetes has been challenged by obstacles to patient accessibility and long-term graft function that may be overcome by integrating emerging technologies in biomaterials, drug delivery and immunomodulation. The hepatic microenvironment and traditional systemic immunosuppression stress the vulnerable islets and contribute to the limited success of transplantation. Locally delivering extracellular matrix proteins and trophic factors can enhance transplantation at extrahepatic sites by promoting islet engraftment, revascularisation and long-term function while avoiding unintended systemic effects. Cell- and cytokine-based therapies for immune cell recruitment and reprogramming can inhibit local and systemic immune system activation that normally attacks transplanted islets. Combined with antigen-specific immunotherapies, states of operational tolerance may be achievable, reducing or eliminating the long-term pharmaceutical burden. Integration of these technologies to enhance engraftment and combat rejection may help to advance the therapeutic efficacy and availability of islet transplantation.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1007/s00125-011-2243-0

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • To achieve progress with islet-cell transplantation, investigators are focusing on xenotransplantation, encapsulation, novel sites for cell delivery, and development of surrogate insulin-producing cells.

    “To achieve progress with islet-cell transplantation, investigators are focusing on xenotransplantation, encapsulation, novel sites for cell delivery (eg, eye), and development of surrogate insulin-producing cells.151”

    From Type 1 diabetes (2014) · cites this paper as [151]

  • Islet transplantation remains an experimental procedure, with ongoing research focusing on new methods using biomaterials, immune modulation, site of delivery, improved vascularisation, and more.

    “Therefore, islet transplantation remains an experimental procedure, with ongoing research focusing on new methods using biomaterials (eg, encapsulation), immune modulation, site of delivery, improved vascularisation, and more.151”

    From Type 1 diabetes (2014) · cites this paper as [151]

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 98

  1. [1]Cryer PE The barrier of hypoglycemia in diabetes Diabetes 2008 57 3169 3176 19033403 PMC2584119
  2. [2]Pambianco G Costacou T Ellis D Becker DJ Klein R Orchard TJ The 30-year natural history of type 1 diabetes complications: the Pittsburgh Epidemiology of Diabetes Complications Study experience Diabetes 2006 55 1463 1469 16644706
  3. [3]Shapiro AM Lakey JR Ryan EA Islet transplantation in seven patients with type 1 diabetes mellitus using a glucocorticoid-free immunosuppressive regimen N Engl J Med 2000 343 230 238 10911004
  4. [4]Soedamah-Muthu SS Fuller JH Mulnier HE Raleigh VS Lawrenson RA Colhoun HM All-cause mortality rates in patients with type 1 diabetes mellitus compared with a non-diabetic population from the UK general practice research database, 1992–1999 Diabetologia 2006 49 660 666 16432708
  5. [5]Hering BJ Kandaswamy R Ansite JD Single-donor, marginal-dose islet transplantation in patients with type 1 diabetes JAMA 2005 293 830 835 15713772
  6. [6]Posselt AM Bellin MD Tavakol M Islet transplantation in type 1 diabetics using an immunosuppressive protocol based on the anti-LFA-1 antibody efalizumab Am J Transplant 2010 10 1870 1880 20659093 PMC2911648
  7. [8]Warnock GL Thompson DM Meloche RM A multiyear analysis of islet transplantation compared with intensive medical therapy on progression of complications in type 1 diabetes Transplantation 2008 86 1762 1766 19104418
  8. [9]Wang RN Rosenberg L Maintenance of beta-cell function and survival following islet isolation requires re-establishment of the islet-matrix relationship J Endocrinol 1999 163 181 190 10556766
  9. [10]Barshes NR Wyllie S Goss JA Inflammation-mediated dysfunction and apoptosis in pancreatic islet transplantation: implications for intrahepatic grafts J Leukoc Biol 2005 77 587 597 15728243
  10. [11]Bennet W Groth CG Larsson R Nilsson B Korsgren O Isolated human islets trigger an instant blood mediated inflammatory reaction: implications for intraportal islet transplantation as a treatment for patients with type 1 diabetes Ups J Med Sci 2000 105 125 133 11095109
  11. [12]Shapiro AM Gallant HL Hao EG The portal immunosuppressive storm: relevance to islet transplantation? Ther Drug Monit 2005 27 35 37 15665744
  12. [13]Nanji SA Shapiro AM Islet transplantation in patients with diabetes mellitus: choice of immunosuppression BioDrugs 2004 18 315 328 15377174
  13. [14]Lau J Carlsson PO Low revascularization of human islets when experimentally transplanted into the liver Transplantation 2009 87 322 325 19202435
  14. [15]Lee Y Ravazzola M Park BH Bashmakov YK Orci L Unger RH Metabolic mechanisms of failure of intraportally transplanted pancreatic beta-cells in rats: role of lipotoxicity and prevention by leptin Diabetes 2007 56 2295 2301 17563069
  15. [16]Hiller WF Klempnauer J Lück R Steiniger B Progressive deterioration of endocrine function after intraportal but not kidney subcapsular rat islet transplantation Diabetes 1991 40 134 140 2015968
  16. [17]Salvay DM Rives CB Zhang X Extracellular matrix protein-coated scaffolds promote the reversal of diabetes after extrahepatic islet transplantation Transplantation 2008 85 1456 1464 18497687 PMC2597660
  17. [18]Pinkse GG Bouwman WP Jiawan-Lalai R Terpstra OT Bruijn JA de Heer E Integrin signaling via RGD peptides and anti-beta1 antibodies confers resistance to apoptosis in islets of Langerhans Diabetes 2006 55 312 317 16443762
  18. [19]Bonner-Weir S Li WC Ouziel-Yahalom L Guo L Weir GC Sharma A Beta-cell growth and regeneration: replication is only part of the story Diabetes 2010 59 2340 2348 20876724 PMC3279552
  19. [20]Kheradmand T Wang S Gibly RF Permanent protection of PLG scaffold transplanted allogeneic islet grafts in diabetic mice treated with ECDI-fixed donor splenocyte infusions Biomaterials 2011 32 4517 4524 21458857 PMC3387923
  20. [21]Aguayo-Mazzucato C Bonner-Weir S Stem cell therapy for type 1 diabetes mellitus Nat Rev Endocrinol 2010 6 139 148 20173775
  21. [22]Blomeier H Zhang X Rives C Polymer scaffolds as synthetic microenvironments for extrahepatic islet transplantation Transplantation 2006 82 452 459 16926587 PMC2648394
  22. [23]Berman DM O’Neil JJ Coffey LC Long-term survival of nonhuman primate islets implanted in an omental pouch on a biodegradable scaffold Am J Transplant 2009 9 91 104 19133931 PMC4441095
  23. [24]Merani S Toso C Emamaullee J Shapiro AM Optimal implantation site for pancreatic islet transplantation Br J Surg 2008 95 1449 1461 18991254
  24. [25]Contreras JL Extrahepatic transplant sites for islet xenotransplantation Xenotransplantation 2008 15 99 101 18447878
  25. [26]Tze WJ Tai J Immunological studies in diabetic rat recipients with a pancreatic islet cell allograft in the brain Transplantation 1989 47 1053 1057 2499961
  26. [27]Whittington KB Solomon SS Lu ZN Selawry HP Islet allografts in the cryptorchid testes of spontaneously diabetic BB/Wor dp rats: response to glucose, glipizide, and arginine Endocrinology 1991 128 2671 2677 1674684
  27. [28]Echeverri GJ McGrath K Bottino R Endoscopic gastric submucosal transplantation of islets (ENDO-STI): technique and initial results in diabetic pigs Am J Transplant 2009 9 2485 2496 19775318
  28. [29]Perez VL Caicedo A Berman DM The anterior chamber of the eye as a clinical transplantation site for the treatment of diabetes: a study in a baboon model of diabetes Diabetologia 2011 54 1121 1126 21360190 PMC3247302
  29. [30]Perez-Basterrechea M Briones RM Alvarez-Viejo M Plasma-fibroblast gel as scaffold for islet transplantation Tissue Eng Part A 2009 15 569 577 18694292
  30. [31]Lim JY Min BH Kim BG A fibrin gel carrier system for islet transplantation into kidney subcapsule Acta Diabetol 2009 46 243 248 19030773
  31. [32]Hiscox AM Stone AL Limesand S Hoying JB Williams SK An islet-stabilizing implant constructed using a preformed vasculature Tissue Eng Part A 2007 14 433 440 18333795
  32. [33]Beck J Angus R Madsen B Britt D Vernon B Nguyen KT Islet encapsulation: strategies to enhance islet cell functions Tissue Eng 2007 13 589 599 17518605
  33. [34]Murua A Portero A Orive G Hernández RM de Castro M Pedraz JL Cell microencapsulation technology: towards clinical application J Control Release 2008 132 76 83 18789985
  34. [35]Lai Y Schneider D Kidszun A Vascular endothelial growth factor increases functional beta-cell mass by improvement of angiogenesis of isolated human and murine pancreatic islets Transplantation 2005 79 1530 1536 15940042
  35. [36]Olsson R Maxhuni A Carlsson P-O Revascularization of transplanted pancreatic islets following culture with stimulators of angiogenesis Transplantation 2006 82 340 347 16906031
  36. [37]Wang W Gu Y Tabata Y Reversal of diabetes in mice by xenotransplantation of a bioartificial pancreas in a prevascularized subcutaneous site Transplantation 2002 73 122 129 11792991
  37. [38]Balamurugan AN Gu Y Tabata Y Bioartificial pancreas transplantation at prevascularized intermuscular space: effect of angiogenesis induction on islet survival Pancreas 2003 26 279 285 12657955
  38. [39]Song HJ Xue WJ Li Y Prolongation of islet graft survival using concomitant transplantation of islets and vascular endothelial cells in diabetic rats Transplant Proc 2010 42 2662 2665 20832565
  39. [40]Thomas FT Contreras JL Bilbao G Ricordi C Curiel D Thomas JM Anoikis, extracellular matrix, and apoptosis factors in isolated cell transplantation Surgery 1999 126 299 304 10455898
  40. [41]Kaido T Yebra M Cirulli V Montgomery AM Regulation of human beta-cell adhesion, motility, and insulin secretion by collagen IV and its receptor α1 β1 J Biol Chem 2004 279 53762 53769 15485856
  41. [42]Ghofaili KA Fung M Ao Z Effect of exenatide on beta cell function after islet transplantation in type 1 diabetes Transplantation 2007 83 24 28 17220786
  42. [43]Giannoukakis N Mi Z Rudert WA Gambotto A Trucco M Robbins P Prevention of beta cell dysfunction and apoptosis activation in human islets by adenoviral gene transfer of the insulin-like growth factor I Gene Ther 2000 7 2015 2022 11175313
  43. [44]Johansson M Olerud J Jansson L Carlsson PO Prolactin treatment improves engraftment and function of transplanted pancreatic islets Endocrinology 2009 150 1646 1653 19095742
  44. [45]Rivas-Carrillo JD Soto-Gutierrez A Navarro-Alvarez N Cell-permeable pentapeptide V5 inhibits apoptosis and enhances insulin secretion, allowing experimental single-donor islet transplantation in mice Diabetes 2007 56 1259 1267 17287463
  45. [46]Gangemi A Salehi P Hatipoglu B Islet transplantation for brittle type 1 diabetes: the UIC protocol Am J Transplant 2008 8 1250 1261 18444920
  46. [47]Pollauf EJ Kim KK Pack DW Small-molecule release from poly(D,L-lactide)/poly(D,L-lactide-co-glycolide) composite microparticles J Pharm Sci 2005 94 2013 2022 16052542
  47. [48]Chen RR Silva EA Yuen WW Mooney DJ Spatio-temporal VEGF and PDGF delivery patterns blood vessel formation and maturation Pharm Res 2007 24 258 264 17191092
  48. [49]Rives CB des Rieux A Zelivyanskaya M Stock SR Lowe WL Jr Shea LD Layered PLG scaffolds for in vivo plasmid delivery Biomaterials 2009 30 394 401 18929408 PMC2642007
  49. [50]Mellor AL Munn DH Creating immune privilege: active local suppression that benefits friends, but protects foes Nat Rev Immunol 2008 8 74 80 18064049
  50. [51]Wood KJ Sakaguchi S Regulatory T cells in transplantation tolerance Nat Rev Immunol 2003 3 199 210 12658268
  51. [52]Olson JK Croxford JL Miller SD Virus-induced autoimmunity: potential role of viruses in initiation, perpetuation, and progression of T cell-mediated autoimmune disease Viral Immunol 2001 14 227 250 11572634
  52. [53]Dufour JM Lord SJ Kin T Comparison of successful and unsuccessful islet/Sertoli cell cotransplant grafts in streptozotocin-induced diabetic mice Cell Transplant 2008 16 1029 1038 18351019
  53. [54]van Duivenvoorde LM van Mierlo GJ Boonman ZF Toes RE Dendritic cells: vehicles for tolerance induction and prevention of autoimmune diseases Immunobiology 2006 211 627 632 16920501
  54. [55]Banchereau J Briere F Caux C Immunobiology of dendritic cells Annu Rev Immunol 2000 18 767 811 10837075
  55. [56]Fu F Li Y Qian S Costimulatory molecule-deficient dendritic cell progenitors (MHC class II+, CD80dim, CD86−) prolong cardiac allograft survival in nonimmunosuppressed recipients Transplantation 1996 62 659 665 8830833 PMC3154742
  56. [57]Ito T Yang M Wang YH Plasmacytoid dendritic cells prime IL-10-producing T regulatory cells by inducible costimulator ligand J Exp Med 2007 204 105 115 17200410 PMC2118437
  57. [58]Colonna M Trinchieri G Liu YJ Plasmacytoid dendritic cells in immunity Nat Immunol 2004 5 1219 1226 15549123
  58. [59]Garrovillo M Ali A Oluwole SF Indirect allorecognition in acquired thymic tolerance: induction of donor-specific tolerance to rat cardiac allografts by allopeptide-pulsed host dendritic cells Transplantation 1999 68 1827 1834 10628758
  59. [60]Sato K Yamashita N Baba M Matsuyama T Modified myeloid dendritic cells act as regulatory dendritic cells to induce anergic and regulatory T cells Blood 2003 101 3581 3589 12511411
  60. [61]Sato K Yamashita N Baba M Matsuyama T Regulatory dendritic cells protect mice from murine acute graft-versus-host disease and leukemia relapse Immunity 2003 18 367 379 12648454
  61. [62]Piccirillo CA Thornton AM Cornerstone of peripheral tolerance: naturally occurring CD4+CD25+ regulatory T cells Trends Immunol 2004 25 374 380 15207505
  62. [63]Shevach EM Mechanisms of Foxp3+ T regulatory cell-mediated suppression Immunity 2009 30 636 645 19464986
  63. [64]Belkaid Y Regulatory T cells and infection: a dangerous necessity Nat Rev Immunol 2007 7 875 888 17948021
  64. [65]Nakamura K Kitani A Strober W Cell contact-dependent immunosuppression by CD4+CD25+ regulatory Tcells is mediated by cell surface-bound transforming growth factor beta J Exp Med 2001 194 629 644 11535631 PMC2195935
  65. [66]Zhang N Schroppel B Lal G Regulatory T cells sequentially migrate from inflamed tissues to draining lymph nodes to suppress the alloimmune response Immunity 2009 30 458 469 19303390 PMC2737741
  66. [67]Pothoven KL Kheradmand T Yang Q Rapamycin-conditioned donor dendritic cells differentiate CD4+CD25+Foxp3+ T cells in vitro with TGF-β1 for islet transplantation Am J Transplant 2010 10 1774 1784 20626386 PMC3995630
  67. [68]Luo X Pothoven KL McCarthy D ECDI-fixed allogeneic splenocytes induce donor-specific tolerance for long-term survival of islet transplants via two distinct mechanisms Proc Natl Acad Sci USA 2008 105 14527 14532 18796615 PMC2567158
  68. [69]Luo X Tarbell KV Yang H Dendritic cells with TGF-β1 differentiate naive CD4+CD25− T cells into islet-protective Foxp3+ regulatory T cells Proc Natl Acad Sci USA 2007 104 2821 2826 17307871 PMC1815265
  69. [70]Maccario R Podesta M Moretta A Interaction of human mesenchymal stem cells with cells involved in alloantigen-specific immune response favors the differentiation of CD4+ T cell subsets expressing a regulatory/suppressive phenotype Haematologica 2005 90 516 525 15820948
  70. [71]Di Nicola M Carlo-Stella C Magni M Human bone marrow stromal cells suppress T-lymphocyte proliferation induced by cellular or nonspecific mitogenic stimuli Blood 2002 99 3838 3843 11986244
  71. [72]Berman DM Willman MA Han D Mesenchymal stem cells enhance allogeneic islet engraftment in nonhuman primates Diabetes 2010 59 2558 2568 20622174 PMC3279532
  72. [74]Corbett JA Sweetland MA Wang JL Lancaster JR Jr McDaniel ML Nitric oxide mediates cytokine-induced inhibition of insulin secretion by human islets of Langerhans Proc Natl Acad Sci USA 1993 90 1731 1735 8383325 PMC45953
  73. [75]Nagata S Suda T Fas and Fas ligand: lpr and gld mutations Immunol Today 1995 16 39 43 7533498
  74. [76]Arnush M Scarim AL Heitmeier MR Kelly CB Corbett JA Potential role of resident islet macrophage activation in the initiation of autoimmune diabetes J Immunol 1998 160 2684 2691 9510167
  75. [77]Contreras JL Eckstein C Smyth CA Activated protein C preserves functional islet mass after intraportal transplantation: a novel link between endothelial cell activation, thrombosis, inflammation, and islet cell death Diabetes 2004 53 2804 2814 15504960
  76. [78]Akima S Hawthorne WJ Favaloro E Tirofiban and activated protein C synergistically inhibit the Instant Blood Mediated Inflammatory Reaction (IBMIR) from allogeneic islet cells exposure to human blood Am J Transplant 2009 9 1533 1540 19459790
  77. [79]Cui W Wilson JT Wen J Thrombomodulin improves early outcomes after intraportal islet transplantation Am J Transplant 2009 9 1308 1316 19459803 PMC2759690
  78. [81]Cassatella MA Meda L Bonora S Ceska M Constantin G Interleukin 10 (IL-10) inhibits the release of proinflammatory cytokines from human polymorphonuclear leukocytes. Evidence for an autocrine role of tumor necrosis factor and IL-1β in mediating the production of IL-8 triggered by lipopolysaccharide J Exp Med 1993 178 2207 2211 8245792 PMC2191270
  79. [82]Sun L Guo RF Newstead MW Standiford TJ Macariola DR Shanley TP Effect of IL-10 on neutrophil recruitment and survival after Pseudomonas aeruginosa challenge Am J Respir Cell Mol Biol 2009 41 76 84 19097982 PMC2701962
  80. [83]Aviles MO Lin CH Zelivyanskaya M The contribution of plasmid design and release to in vivo gene expression following delivery from cationic polymer modified scaffolds Biomaterials 2010 31 1140 1147 19892398 PMC2821673
  81. [84]Ali OA Huebsch N Cao L Dranoff G Mooney DJ Infection-mimicking materials to program dendritic cells in situ Nat Mater 2009 8 151 158 19136947 PMC2684978
  82. [85]Viney JL Mowat AM O’Malley JM Williamson E Fanger NA Expanding dendritic cells in vivo enhances the induction of oral tolerance J Immunol 1998 160 5815 5825 9637492
  83. [86]Shields JD Kourtis IC Tomei AA Roberts JM Swartz MA Induction of lymphoidlike stroma and immune escape by tumors that express the chemokine CCL21 Science 2010 328 749 752 20339029
  84. [87]Battaglia M Stabilini A Draghici E Rapamycin and interleukin-10 treatment induces T regulatory type 1 cells that mediate antigen-specific transplantation tolerance Diabetes 2006 55 40 49 16380475
  85. [88]Kimura F Gotoh M Tanaka T Locally expressed CTLA4-Ig in a pancreatic beta-cell line suppresses accelerated graft rejection response induced by donor-specific transfusion Diabetologia 2002 45 831 840 12107727
  86. [89]Papeta N Chen T Vianello F Long-term survival of transplanted allogeneic cells engineered to express a T cell chemorepellent Transplantation 2007 83 174 183 17264814
  87. [90]Reddy ST van der Vlies AJ Simeoni E Exploiting lymphatic transport and complement activation in nanoparticle vaccines Nat Biotechnol 2007 25 1159 1164 17873867
  88. [91]Zheng XX Markees TG Hancock WW CTLA4 signals are required to optimally induce allograft tolerance with combined donor-specific transfusion and anti-CD154 monoclonal antibody treatment J Immunol 1999 162 4983 4990 10202046
  89. [92]Pearson TC Madsen JC Larsen CP Morris PJ Wood KJ Induction of transplantation tolerance in adults using donor antigen and anti-CD4 monoclonal antibody Transplantation 1992 54 475 483 1384183
  90. [93]Punch JD Tono T Qin L Bishop DK Bromberg JS Tolerance induction by anti-CD2 plus anti-CD3 monoclonal antibodies: evidence for an IL-4 requirement J Immunol 1998 161 1156 1162 9686574
  91. [94]Xu L Villain M Galin FS Araga S Blalock JE Prevention and reversal of experimental autoimmune myasthenia gravis by a monoclonal antibody against acetylcholine receptor-specific T cells Cell Immunol 2001 208 107 114 11333143
  92. [95]Braley-Mullen H Tompson JG Sharp GC Kyriakos M Suppression of experimental autoimmune thyroiditis in guinea pigs by pretreatment with thyroglobulin-coupled spleen cells Cell Immunol 1980 51 408 413 6154539
  93. [96]Dua HS Gregerson DS Donoso LA Inhibition of experimental autoimmune uveitis by retinal photoreceptor antigens coupled to spleen cells Cell Immunol 1992 139 292 305 1733504
  94. [97]Vandenbark AA Vainiene M Ariail K Miller SD Offner H Prevention and treatment of relapsing autoimmune encephalomyelitis with myelin peptide-coupled splenocytes J Neurosci Res 1996 45 430 438 8872903
  95. [98]Miller SD Turley DM Podojil JR Antigen-specific tolerance strategies for the prevention and treatment of autoimmune disease Nat Rev Immunol 2007 7 665 677 17690713
  96. [99]Nano R Clissi B Melzi R Islet isolation for allotransplantation: variables associated with successful islet yield and graft function Diabetologia 2005 48 906 912 15830183
  97. [100]Noguchi H Production of pancreatic beta-cells from stem cells Curr Diabetes Rev 2010 6 184 190 20380628
  98. [101]Hering BJ Walawalkar N Pig-to-nonhuman primate islet xenotransplantation Transpl Immunol 2009 21 81 86 19427901

Cited by

Sorted by citations

Authors
Gibly, R. F., Graham, J. G., Luo, X., Lowe, W. L., Hering, B. J., & Shea, L. D.
Affiliations
  • Northwestern University (US)
  • University of Minnesota (US)
Corresponding author
Shea, L. D.
ORCID
Venue
Diabetologia
Publisher
Springer Science and Business Media LLC
Published
2011-08-10
Volume
54
Issue
10
Pages
2494-505
ISSN
  • 0012-186X (ISSN-L)
  • 1432-0428
DOI
10.1007/s00125-011-2243-0
PMC
PMC3193607
OpenAlex
W1968959177
Cited by
143
References
2
Citations by year
2026: 2 · 2025: 5 · 2024: 8 · 2023: 4 · 2022: 11 · 2021: 12 · 2020: 17 · 2019: 9 · 2018: 8 · 2017: 12 · 2016: 11 · 2015: 9 · 2014: 9 · 2013: 14 · 2012: 12
FWCI
2.02
Type
journal article
Language
en
Open access
Licence
www.springer.com/tdm (tdm)
Locations
  • Diabetologia (publishedVersion)
  • PubMed (publishedVersion)
  • PubMed Central (acceptedVersion)
Funders
  • National Institutes of Health
  • National Institute of Allergy and Infectious Diseases (U01AI089316)
  • National Institute of Diabetes and Digestive and Kidney Diseases (DP2DK083099, F30 DK846492)
  • National Institute of Biomedical Imaging and Bioengineering (R21EB009502, R01EB009910)
  • National Center for Research Resources (UL1RR025741)
Topics
  • Health Sciences › Medicine › Surgery › Pancreatic function and diabetes
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Diabetes and associated disorders
  • Health Sciences › Medicine › Surgery › Tissue Engineering and Regenerative Medicine
Keywords
islet transplantation, type 1 diabetes, islet engraftment, immune rejection, hepatic microenvironment, extracellular matrix, trophic factors, local drug delivery, immunomodulation, cell therapy, cytokine therapy, antigen-specific immunotherapy, immune tolerance, biomaterials
MeSH terms
Biotechnology, Humans, Islets of Langerhans Transplantation, Tissue Engineering, Immunomodulation

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review